MBRX vs. FLGC, SYBX, ASBP, GOVX, ALLR, PRPH, UBX, EDSA, VYNE, and ME
Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Flora Growth (FLGC), Synlogic (SYBX), Aspire Biopharma (ASBP), GeoVax Labs (GOVX), Allarity Therapeutics (ALLR), ProPhase Labs (PRPH), UNITY Biotechnology (UBX), Edesa Biotech (EDSA), VYNE Therapeutics (VYNE), and 23andMe (ME). These companies are all part of the "pharmaceutical products" industry.
Moleculin Biotech vs. Its Competitors
Moleculin Biotech (NASDAQ:MBRX) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
Moleculin Biotech currently has a consensus target price of $4.00, indicating a potential upside of 1,051.08%. Flora Growth has a consensus target price of $4.00, indicating a potential upside of 572.72%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Moleculin Biotech is more favorable than Flora Growth.
Flora Growth has higher revenue and earnings than Moleculin Biotech.
In the previous week, Flora Growth had 2 more articles in the media than Moleculin Biotech. MarketBeat recorded 4 mentions for Flora Growth and 2 mentions for Moleculin Biotech. Flora Growth's average media sentiment score of 1.06 beat Moleculin Biotech's score of 0.62 indicating that Flora Growth is being referred to more favorably in the news media.
15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 36.0% of Flora Growth shares are held by institutional investors. 1.9% of Moleculin Biotech shares are held by company insiders. Comparatively, 12.6% of Flora Growth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Moleculin Biotech has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500.
Moleculin Biotech has a net margin of 0.00% compared to Flora Growth's net margin of -24.85%. Flora Growth's return on equity of -216.49% beat Moleculin Biotech's return on equity.
Summary
Flora Growth beats Moleculin Biotech on 9 of the 13 factors compared between the two stocks.
Get Moleculin Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Moleculin Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:MBRX) was last updated on 7/3/2025 by MarketBeat.com Staff
